Showing results (1-10 of 114) with videos related to

Sort By:
Pageof 12
Oncotarget|July 27, 2010
Targeting TOR dependence in cancerMatthew R Janes, David A Fruman
Science Signaling|April 23, 2009
Immune regulation by rapamycin: moving beyond T cellsMatthew R Janes, David A Fruman
Methods in Molecular Biology (Clifton, N.J.)|November 30, 2011
The in vivo evaluation of active-site TOR inhibitors in models of BCR-ABL+ leukemiaMatthew R Janes, David A Fruman
Plos One|March 4, 2014
Resistance to mTOR kinase inhibitors in lymphoma cells lacking 4EBP1Sharmila Mallya, Briana A Fitch, J Scott Lee, et al.
Molecular Endocrinology (Baltimore, Md.)|March 26, 2011
B-1 cell lymphoma in mice lacking the steroid and xenobiotic receptor, SXRStephanie C Casey, Edward L Nelson, Gina M Turco, et al.
The Journal of Clinical Investigation|August 16, 2008
Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cellsMichael G Kharas, Matthew R Janes, Vanessa M Scarfone, et al.
Current Topics in Microbiology and Immunology|June 22, 2010
Regulatory subunits of class IA PI3KDavid A Fruman
Current Opinion in Immunology|May 12, 2004
Phosphoinositide 3-kinase and its targets in B-cell and T-cell signalingDavid A Fruman
Cancer Cell|June 14, 2011
A lipid kinase cousin cooperates to promote cancerBrandon Beagle, David A Fruman
Immunological Reviews|March 18, 2009
Fine tuning the immune response with PI3KDavid A Fruman, Georges Bismuth
Pageof 12